Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Phase 2

Terminated

Conditions: Prostate Cancer
Metastatic Castrate-Resistant Prostate Cancer
PSA

Interventions: Drug: OGX-427
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2012-09-10

Last Posted Date: 2022-07-11

Lead Sponsor: Costantine Albany

Target Recruit Count: 72

Registration Number: NCT01681433

Locations: 🇺🇸
IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸
Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States
🇺🇸
IU Health Goshen Hospital, Goshen, Indiana, United States

and more 13 locations

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Phase 4

Terminated

Conditions: Chronic Rhinosinusitis Without Nasal Polyps

Interventions: Drug: Prednisone
Drug: Topical mometasone

First Posted Date: 2012-08-30

Last Posted Date: 2018-03-30

Lead Sponsor: Northwestern University

Target Recruit Count: 9

Registration Number: NCT01676415

Locations: 🇺🇸
: Northwestern Medical Faculty Foundation (NMFF) Sinus and Allergy Center, Chicago, Illinois, United States

Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis

Not Applicable

Completed

Conditions: Cellulitis

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2012-08-23

Last Posted Date: 2021-02-10

Lead Sponsor: Albert Einstein Healthcare Network

Target Recruit Count: 42

Registration Number: NCT01671423

Locations: 🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Phase 2

Withdrawn

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: nilotinib
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: methotrexate
Drug: cytarabine
Drug: prednisone
Drug: mesna
Drug: dexamethasone
Drug: leucovorin calcium

First Posted Date: 2012-08-21

Last Posted Date: 2015-10-30

Lead Sponsor: Mayo Clinic

Registration Number: NCT01670084

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Orteronel
Drug: Orteronel Placebo
Drug: Prednisone

First Posted Date: 2012-08-16

Last Posted Date: 2018-03-20

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 137

Registration Number: NCT01666314

Locations: 🇺🇸
Urology Cancer Center, PC, Omaha, Nebraska, United States

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Phase 3

Terminated

Conditions: Diffuse Large B Cell Lymphoma CD20 Positive

Interventions: Drug: Rituximab
Drug: GA101
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Bleomycin
Drug: Vindesin
Drug: Vincristine

First Posted Date: 2012-08-07

Last Posted Date: 2018-03-07

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 671

Registration Number: NCT01659099

Locations: 🇧🇪
Clinique universitaire Saint LUC, Bruxelles, Belgium
🇧🇪
CHU Ambroise Paré, Mons, Belgium
🇧🇪
Clinique Sainte Elisabeth, Namur, Belgium

and more 119 locations

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Phase 2

Completed

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: enzalutamide
Drug: abiraterone acetate
Drug: prednisone

First Posted Date: 2012-07-26

Last Posted Date: 2024-12-10

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 60

Registration Number: NCT01650194

Locations: 🇺🇸
Site US2492 MD Anderson Cancer Ctr, Houston, Texas, United States

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: CABAZITAXEL (XRP6258)
Drug: Prednisone
Drug: Ciprofloxacin
Drug: G-CSF (Granulocyte colony-stimulating factor)

First Posted Date: 2012-07-25

Last Posted Date: 2016-07-06

Lead Sponsor: Sanofi

Target Recruit Count: 45

Registration Number: NCT01649635

Locations: 🇧🇷
Investigational Site Number 006, Lajeado, Brazil
🇧🇷
Investigational Site Number 005, Porto Alegre, Brazil
🇧🇷
Investigational Site Number 002, São Paulo, Brazil

and more 3 locations

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Castration Resistant Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2012-07-11

Last Posted Date: 2020-08-17

Lead Sponsor: Terence Friedlander, MD

Target Recruit Count: 41

Registration Number: NCT01637402

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Phase 1

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Valproate
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2012-06-19

Last Posted Date: 2018-03-12

Lead Sponsor: Lund University Hospital

Target Recruit Count: 50

Registration Number: NCT01622439

Locations: 🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy